Burga Ana M, Tavassoli Fattaneh A
Department of Breast and Gynecologic Pathology, Armed Forces Institute of Pathology, Washington, DC, USA.
Am J Surg Pathol. 2003 Mar;27(3):343-8. doi: 10.1097/00000478-200303000-00007.
Biphasic breast tumors with benign ductal elements and a sarcomatous stroma lacking a phyllodes architecture are a source of diagnostic problems, particularly because of the lack of an appropriate designation. At the Armed Forces Institute of Pathology, we have used the term "periductal stromal sarcoma" to distinguish these from phyllodes tumors. All cases coded as periductal stromal sarcoma or PDSH were retrieved from the files of the Armed Forces Institute of Pathology. Cases that fulfilled the following criteria were included in this study. The histologic features of periductal stromal sarcoma were defined as 1) a predominantly spindle cell stromal proliferation of variable cellularity and atypia around open tubules and ducts devoid of a phyllodes pattern, 2) one or more often multiple nodules separated by adipose tissue, 3) stromal mitotic activity of >/=3/10 high power fields, and 4) stromal infiltration into surrounding breast tissue. Criteria for periductal stromal hyperplasia included 1) nodular, bland stroma growing as cuffs around normal or altered ducts, 2) no to minimal atypia, and 3) at most 0-2 stromal mitotic figures per 10 high power fields. Immunohistochemistry was used to further characterize these neoplasms. Of the cases retrieved, 20 qualified as periductal stromal sarcoma and seven as periductal stromal hyperplasia. Patients with periductal stromal sarcoma ranged in age from 37 to 89 years (mean 55.3 years). The tumors measured 0.2-6.0 cm (mean 2.97 cm). Eighteen patients had excisional biopsies and two had partial mastectomies. Overall follow-up time ranged from 1 to 72 months (mean 25.3 months) with two patients (10%) showing recurrence or probable metastasis. The neoplastic cells of periductal stromal sarcoma were at least focally immunoreactive for CD34 (13 of 15), CD117 (6 of 15), less reactive for actin (HHF35, 2 of 15), and negative for estrogen and progesterone receptors. Periductal stromal sarcoma is a useful descriptive designation for generally low-grade biphasic tumors with sarcomatous stroma that do not have features of a phyllodes tumor. The development of focal phyllodes pattern in the recurrent tumor as well as development of a specific soft tissue sarcoma in one of the above cases suggest that some and possibly all periductal stromal sarcoma may evolve into a phyllodes tumor with time. Given the presence of infiltrative margins, excision with a rim of uninvolved tissue is required.
具有良性导管成分和缺乏叶状结构的肉瘤样间质的双相性乳腺肿瘤是诊断难题的来源,尤其是因为缺乏合适的命名。在武装部队病理研究所,我们使用了“导管周围间质肉瘤”这一术语来将这些肿瘤与叶状肿瘤区分开来。所有编码为导管周围间质肉瘤或PDSH的病例均从武装部队病理研究所的档案中检索出来。符合以下标准的病例纳入本研究。导管周围间质肉瘤的组织学特征定义为:1)围绕开放的小管和导管存在以梭形细胞为主的间质增生,细胞密度和异型性各异,且无叶状结构;2)一个或多个(通常为多个)结节被脂肪组织分隔;3)间质有丝分裂活性≥3/10个高倍视野;4)间质浸润周围乳腺组织。导管周围间质增生的标准包括:1)结节状、温和的间质以袖套状围绕正常或改变的导管生长;2)无或仅有极少异型性;3)每10个高倍视野最多有0 - 2个间质有丝分裂象。免疫组织化学用于进一步对这些肿瘤进行特征描述。在检索到的病例中,20例符合导管周围间质肉瘤,7例符合导管周围间质增生。导管周围间质肉瘤患者年龄在37至89岁之间(平均55.3岁)。肿瘤大小为0.2 - 6.0 cm(平均2.97 cm)。18例患者接受了切除活检,2例接受了乳房部分切除术。总体随访时间为1至72个月(平均25.3个月),2例患者(10%)出现复发或可能的转移。导管周围间质肉瘤的肿瘤细胞至少在局部对CD34(15例中的13例)、CD117(15例中的6例)呈免疫反应,对肌动蛋白(HHF35,15例中的2例)反应较弱,对雌激素和孕激素受体呈阴性。导管周围间质肉瘤是一个有用的描述性命名,用于一般为低级别、具有肉瘤样间质且无叶状肿瘤特征的双相性肿瘤。复发性肿瘤中出现局灶性叶状结构以及上述病例中的一例发生特定软组织肉瘤提示,一些甚至可能所有导管周围间质肉瘤可能随时间演变为叶状肿瘤。鉴于存在浸润性边缘,需要切除带有一圈未受累组织的肿瘤。